Back to results
US 2026/0159853 A1Published application
Lymphocyte targeted lentiviral vectors
AssigneeKelonia Therapeutics, Inc.
InventorsMolly R. Perkins, Kevin M. Friedman
Life of this patent
Estimating the term…
Abstract
Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.
Claims30
A lentiviral vector particle, comprising:
- (a) a viral envelope comprising:
- (i) a heterologous lymphocyte targeting protein comprising:
- an extracellular T cell targeting domain;
- and a transmembrane domain;
- and
- (ii) a mutated VSV-G envelope protein comprising an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO:
- 90, wherein the mutated VSV-G envelope protein comprises an amino acid substitution at position 1182;
- and
- (b) a lentiviral vector comprising an expression cassette that comprises a heterologous transgene encoding a chimeric antigen receptor (CAR).
6 more elements
A lentiviral vector particle, comprising:
- (a) a viral envelope comprising:
- (i) a heterologous lymphocyte targeting protein comprising:
- an extracellular T cell targeting domain;
- and a transmembrane domain;
- and
- (ii) a mutated VSV-G envelope protein comprising an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO:
- 90, wherein the mutated VSV-G envelope protein comprises an amino acid substitution at position 1182;
- and
- (b) a lentiviral vector comprising an expression cassette that comprises a heterologous transgene encoding a chimeric antigen receptor (CAR).
6 more elements
A lentiviral vector particle, comprising:
- (a) a viral envelope comprising:
- (i) a heterologous lymphocyte targeting protein comprising:
- an extracellular T cell targeting domain;
- and a transmembrane domain;
- and
- (ii) a mutated VSV-G envelope protein comprising an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO:
- 90, wherein the mutated VSV-G envelope protein comprises an amino acid substitution at position 1182;
- and
- (b) a lentiviral vector comprising an expression cassette that comprises a heterologous transgene encoding a chimeric antigen receptor (CAR).
6 more elements
Dependencies are inferred from the claim text.